Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
about
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseReview article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisOptimizing the use of biological therapy in patients with inflammatory bowel diseaseEvolving Concepts in Phases I and II Drug Development for Crohn's Disease.Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.Therapeutic drug monitoring in patients with inflammatory bowel diseaseInfliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn DiseasePharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.Infliximab for the treatment of pediatric ulcerative colitis.Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment responseReview article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors.Targeting TNF-α for the treatment of inflammatory bowel disease.TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseaseDashboard systems: implementing pharmacometrics from bench to bedside.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease.Challenges and considerations for development of therapeutic proteins in pediatric patients.Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety.Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases.Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis.Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.Drug Development of Therapeutic Monoclonal Antibodies.Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Learning Health Systems as Facilitators of Precision Medicine.Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.The underlying inflammatory chronic disease influences infliximab pharmacokinetics.Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.
P2860
Q26745721-BE7BDF77-A381-4D8C-B820-96D743ABDD20Q26823221-22C5506A-A57F-44F8-BBF8-F5DA3B90F9B7Q27025513-84A5F5AA-2AB1-471F-9B1B-D1DD20CAAC2AQ30248641-61E3193F-5D39-483F-82EF-7D566D22E311Q35023731-93D0C899-E76C-4148-98FA-D2C9A1F97F6EQ35140715-64FAA2B2-F4E5-4D07-A03C-10531222FE99Q36828605-4DFEBDD9-596F-40BE-9F26-D625E9044CA0Q37523503-BE86AF38-58DD-486D-B565-F17FBCD837A9Q38067127-DCEC8F80-92CF-473C-B9FE-E27C081F7877Q38118313-2898DB7D-9AD7-4FF4-A692-291987F12722Q38121115-7D173D8A-B5FF-4CA5-94FF-AACD883D98E4Q38151885-8BBE27AA-8284-4783-8E85-29B4DF00FC91Q38160905-7129A6AD-1189-4CC4-9C66-B60AADE40B13Q38206507-D4BBB274-6F62-4AF9-B3D6-9A18153038A0Q38221759-42EB7BC4-D7C4-4245-85C4-7914DF8264FFQ38291356-0145B692-C66B-4E3B-9D23-B0B49952D753Q38323592-BB8E1DB7-E19A-4A91-BB2E-CA0D50F51BE6Q38364457-848407BF-30E5-46AA-8EEC-8A6F039BC25CQ38364464-028E34F0-901B-40AF-B34E-91CA73E84643Q38364465-AAADDB8F-3A2E-47FE-9EB4-E225FB865067Q38435506-A968B1F6-5C07-4A70-9176-3492391A44EFQ38501680-54386ED9-C0B7-421F-9F49-266BF8E6E7CFQ38540353-195B2D2B-4618-47E5-91D9-21F004350C8DQ38586029-F15C38BA-6575-43E3-A98C-D727F687FB80Q38591244-818B2F13-0B2B-41A2-B186-679B3EE4DE41Q38619950-3A6541CD-4D8D-4A56-B353-D18CE8710191Q38631012-B2FCD0A5-11AF-4C06-8296-F61691ABACB6Q38652276-917AD1FE-6A99-43CE-A45D-09DD1BD80BF7Q38798678-CA779E2F-10A8-4312-AB3D-4F90B7E5204BQ38856947-72EBFDFE-B580-4B6C-8940-AEA1C5551FFDQ38869663-7EEE91B4-270B-44F2-BEF8-6C18FD3CCAE3Q38876360-71E2E45C-94BF-4A11-A139-B36FA2260C70Q38963689-C69BC07C-48DA-42CF-8AF2-6599F7F199ACQ39016810-3CD0E275-EEB9-4DF4-9EA7-E56FFFBA3E15Q39041482-EC7CF067-13B6-4A42-AA7A-1ACE14761AE8Q41308535-7891BD08-FF61-4888-9F29-E5D95F028C14Q41416145-0820B6F0-2D0F-4810-8684-ACA1540D614AQ41482221-74453A48-3254-4513-A4AA-DEA54DB3901BQ42373188-0494E94E-D738-4F2F-B1AB-1467A3340E1CQ43988900-B26A1C01-2BE2-4A1B-AC44-A3304FF80B38
P2860
Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@ast
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@en
type
label
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@ast
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@en
prefLabel
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@ast
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@en
P2093
P1476
Pharmacokinetic properties of ...... m 2 phase III clinical trials.
@en
P2093
Adedigbo A Fasanmade
Honghui Zhou
Hugh M Davis
Marion Blank
Omoniyi J Adedokun
P304
P356
10.1016/J.CLINTHERA.2011.06.002
P577
2011-07-07T00:00:00Z